Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Alex Baxter

Senior Analyst/Programmer

Alex Baxter is a senior developer in the Web Based Trials Programming Team, which specialises in developing web applications for administering NDPH clinical trials. He has worked on many trials during his time at CTSU, including international large multi-centre randomised clinical trials in the renal and vascular areas: starting with SHARP (Study of Heart and Renal Protection) and the pilot studies UK-HARP-I and UK-HARP-II; THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events); REVEAL (Randomised Evaluation of the Effects of Anacetrapib through Lipid-modification), ORION-4 (of inclisiran in preventing heart attacks and strokes), EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin), and ASCEND PLUS (in the ASCEND - A Study of Cardiovascular Events iN Diabetes – trial series, examining semaglutide for reduction of vascular events in people with type 2 diabetes). 

Additionally, Alex has assisted with epidemiological studies and trial meta-analysis, including: ATT (Anti-Thrombotic Treatment Trialists’ Collaboration), CTT (Cholesterol Treatment Trialists' Collaboration), and as architect and lead developer for the UK Biobank Access Management System (AMS2). 

Prior to joining CTSU in 2000, Alex worked for 5 years as a data manager and developer on ACST (Asymptomatic Carotid Surgery Trial), a CTSU-supported external trial based on St. Mary’s Hospital Medical School (Imperial College School of Medicine).